Sarepta Therapeutics (SRPT) Climbs 20% After Announcing U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

Visit StreetInsider.com at http://www.streetinsider.com/Momentum+Movers/Sarepta+Therapeutics+%28SRPT%29+Climbs+20%25+After+Announcing+U.S.+FDA+Acceptance+of+an+Efficacy+Supplement+to+Expand+the+ELEVIDYS+Indication/22791792.html for the full story.